MedPath

Prasterone

Generic Name
Prasterone
Brand Names
Intrarosa
Drug Type
Small Molecule
Chemical Formula
C19H28O2
CAS Number
53-43-0
Unique Ingredient Identifier
459AG36T1B
Background

Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Dehydroepiandrosterone (DHEA) can be converted to testosterone; androstenedione; estradiol; and estrone. Most of DHEA is sulfated (dehydroepiandrosterone sulfate) before secretion.

In the United States, DHEA or DHEAS have been advertised with claims that they may be beneficial for a wide variety of ailments. DHEA and DHEAS are readily available in the United States, where they are marketed as over-the-counter dietary supplements. In November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

In Canada, a prescription is required to buy DHEA.

Indication

DHEA is taken as a supplement for a variety of unsubstantiated indications. The following indications have shown promise and are backed up by some scientific evidence: schizophrenia (DHEA may be more effective in women than men); improving the appearance of older people’s skin (taking DHEA by mouth seems to increase skin thickness and moisture, and decrease facial “age spots” in elderly men and women); improving ability to achieve an erection in men with sexual dysfunction. Additionally, DHEA has shown promise in improving symptoms of lupus (SLE). Taking DHEA by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed. DHEA may also help SLE symptoms such as muscle ache and mouth ulcers. DHEA also seems to strengthen bones in SLE patients being treated with high-dose steroids (corticosteroids).

DHEA also shows promise in the treatment of osteoporosis. Taking DHEA by mouth daily seems to improve bone mineral density (BMD) in older women and men with osteoporosis or osteopenia (pre-osteoporosis). DHEA may also increase BMD in young women with the eating disorder called anorexia nervosa. DHEA is often prescribed in India for the induction of ovulation to improve chances of pregnancy.

Associated Conditions
Moderate Dyspareunia, Severe Dyspareunia

Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue

Phase 4
Conditions
Sjogren's Syndrome
Interventions
First Posted Date
2007-10-12
Last Posted Date
2007-11-04
Lead Sponsor
University of Helsinki
Target Recruit Count
107
Registration Number
NCT00543166
Locations
🇫🇮

Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland

Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer

Phase 1
Terminated
Conditions
Breast Cancer
First Posted Date
2007-08-15
Last Posted Date
2012-07-24
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
6
Registration Number
NCT00516542
Locations
🇺🇸

Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Six Months DHEA Treatment in Female Adrenal Failure

Not Applicable
Completed
Conditions
Adrenal Insufficiency
First Posted Date
2007-05-10
Last Posted Date
2007-05-10
Lead Sponsor
University of Aarhus
Target Recruit Count
10
Registration Number
NCT00471900

Does DHEA Enhance the Effects of Exercise in Postmenopausal Women?

Not Applicable
Completed
Conditions
Aging
First Posted Date
2007-02-14
Last Posted Date
2011-03-23
Lead Sponsor
Mayo Clinic
Target Recruit Count
32
Registration Number
NCT00434915
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy

Phase 1
Completed
Conditions
Vaginal Atrophy
Interventions
Drug: Placebo
First Posted Date
2007-02-01
Last Posted Date
2017-04-07
Lead Sponsor
CHU de Quebec-Universite Laval
Target Recruit Count
40
Registration Number
NCT00429806
Locations
🇨🇦

Clinique des traitements hormonaux CHUL Research Center, Quebec, Canada

Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome

Phase 2
Completed
Conditions
Lupus Erythematosus, Systemic
Sjogren's Syndrome
First Posted Date
2006-10-25
Last Posted Date
2006-10-25
Lead Sponsor
UMC Utrecht
Target Recruit Count
120
Registration Number
NCT00391924
Locations
🇳🇱

University Medical Center Groningen, Groningen, Netherlands

🇳🇱

University Medical Center Utrecht, Utrecht, Netherlands

Effect of Dehydroepiandrosterone (DHEA) on Hot Flashes in Postmenopausal Women

Phase 2
Completed
Conditions
Hot Flashes
Interventions
Drug: Placebos
First Posted Date
2006-04-24
Last Posted Date
2017-04-07
Lead Sponsor
CHU de Quebec-Universite Laval
Target Recruit Count
50
Registration Number
NCT00317148
Locations
🇨🇦

Clinique des Traitements Hormonaux, Sainte-Foy, Quebec, Canada

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

Phase 2
Completed
Conditions
Anorexia Nervosa
Interventions
Other: Placebo (Sugar Pill)
Drug: Hormone replacement therapy (estrogen/progestin)
First Posted Date
2006-04-05
Last Posted Date
2018-04-11
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
80
Registration Number
NCT00310791
Locations
🇺🇸

Children's Hospital Boston, Boston, Massachusetts, United States

Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms

Phase 3
Completed
Conditions
Quality of Life
Menopausal Syndrome
Libido Disorder
Interventions
First Posted Date
2006-02-10
Last Posted Date
2016-03-16
Lead Sponsor
Monash University
Target Recruit Count
240
Registration Number
NCT00289926
Locations
🇦🇺

Women's Health Research Program, Monash University, The Alfred Hospital, Melbourne, Victoria, Australia

Effect of DHEA on Skin Aging in Postmenopausal Women

Phase 3
Completed
Conditions
Skin Aging
Quality of Life
Interventions
First Posted Date
2005-11-04
Last Posted Date
2017-04-07
Lead Sponsor
CHU de Quebec-Universite Laval
Target Recruit Count
150
Registration Number
NCT00248989
Locations
🇨🇦

Clinique des Traitements Hormonaux- CHUL Research Center, Sainte-Foy, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath